M-A: Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus.

Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials – BMC Endocrine Disorders

Commentary on Twitter

https://twitter.com/kamleshkhunti/status/1526474237481041921

Under a http://creativecommons.org/licenses/by/4.0/ license